The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | QuANTUM-First Q-TWiST analysis supports quizartinib in FLT3-ITD-positive AML
Jorge Cortes, MD, The University of Alabama at Birmingham, Birmingham, AL, discusses findings from a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis from the Phase III QuANTUM-First trial (NCT02668653) comparing quizartinib versus placebo in newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML). He highlights that quizartinib improved meaningful time spent in remission without significant toxicity, further supporting the clinical benefit of adding quizartinib to standard chemotherapy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a very interesting analysis that’s called the skew twist. That’s sort of an acronym that we use. And it’s when you look at these randomized studies and there is a survival benefit of one drug versus the other, the question is how much is that just because they leave more or less than the other arm driven by time that you spend with a lot of side effects in the hospital anyway or how much of that survival benefit could be because of rescue after a relapse because all of that is survival but is invaluable...
This is a very interesting analysis that’s called the skew twist. That’s sort of an acronym that we use. And it’s when you look at these randomized studies and there is a survival benefit of one drug versus the other, the question is how much is that just because they leave more or less than the other arm driven by time that you spend with a lot of side effects in the hospital anyway or how much of that survival benefit could be because of rescue after a relapse because all of that is survival but is invaluable. So this analysis focuses on the time, the valuable time, the time that the patient has without side effects, and the time that the patient has without need for additional therapies and other things. So when you look at that valuable time, we see that there’s particular benefits for quizartinib and mostly driven by the higher rate of responses and longer remission duration and so on. It’s not so much from the safety point of view that there are actually some areas where there’s a little bit more side effects, but because of the high rate of response and duration of remission and all of that, that valuable time becomes significantly better. So that emphasizes the value of the quizartinib combination with standard chemotherapy versus standard chemotherapy alone as something that really benefits the patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
